In recent years, anti-VEGF drugs have been widely employed to treat fundus diseases such as nAMD, DME, and RVO, and have exhibited promising results.[9–11] Although it has been reported previously that intravitreal injection of anti-VEGF drugs might lead to complications such as vitreous hemorrhage, endophthalmitis and intraocular pressure increase,[12] there are few reports describing the possible influence of corneal nerve. This evidence concerns the gene VEGFA and endophthalmitis.